Johnson & White Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.2M Buy
4,760
+28
+0.6% +$6.02K 0.45% 48
2026
Q1
$1.03M Buy
4,732
+40
+0.9% +$8.87K 0.44% 46
2025
Q4
$1.07M Sell
4,692
-28
-0.6% -$6.38K 0.47% 47
2025
Q3
$1.09M Sell
4,720
-974
-17% -$198K 0.5% 44
2025
Q2
$1.06M Sell
5,694
-23
-0.4% -$4.28K 0.53% 44
2025
Q1
$1.2M Buy
5,717
+54
+1% +$10.5K 0.67% 36
2024
Q4
$1.02M Sell
5,663
-453
-7% -$83.3K 0.61% 38
2024
Q3
$1.21M Buy
6,116
+242
+4% +$45.2K 1.04% 24
2024
Q2
$1.01M Buy
5,874
+443
+8% +$73.4K 0.96% 25
2024
Q1
$989K Buy
5,431
+436
+9% +$75.1K 0.72% 37
2023
Q4
$774K Buy
4,995
+198
+4% +$28.9K 0.64% 40
2023
Q3
$715K Buy
4,797
+108
+2% +$15.9K 0.65% 39
2023
Q2
$632K Buy
4,689
+167
+4% +$24.5K 0.87% 24
2023
Q1
$721K Buy
+4,522
New +$691K 0.64% 37
2022
Q4
Sell
-1,745
Closed -$234K 78
2022
Q3
$234K Buy
+1,745
New +$250K 0.26% 68

Other funds holding ABBV

Johnson & White Wealth Management's ABBV Position: Q2 2026 in Review

Johnson & White Wealth Management increased its AbbVie (ABBV) stake by 0.59% in Q2 2026, buying an estimated $6.02K and bringing the position to 4,760 shares worth $1.2M. The position accounts for 0.45% of the portfolio, ranked #48.

Johnson & White Wealth Management first reported a position in ABBV in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.21M in Q3 2024. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Johnson & White Wealth Management held 4,760 shares of AbbVie worth $1.2M as of Q2 2026.
  • Johnson & White Wealth Management bought 28 AbbVie shares in Q2 2026, an estimated $6.02K.
  • AbbVie made up 0.45% of Johnson & White Wealth Management's portfolio in Q2 2026, its #48 holding.
  • Johnson & White Wealth Management first reported a position in AbbVie in Q3 2022 and has held it in 15 quarters since.
  • Johnson & White Wealth Management's AbbVie position peaked at $1.21M in Q3 2024.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Johnson & White Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.